Literature DB >> 18585112

Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.

Siyamek Neragi-Miandoab1, William G Richards, David J Sugarbaker.   

Abstract

AIM: The survival of patients with malignant pleural mesothelioma (MPM) who do not seek treatment ranges from 4 to 12 months. To date, the optimal procedure for resection of malignant pleural mesothelioma is controversial, extrapleural pneumonectomy has been most consistently associated with long-term survival and has provided the most radical cytoreduction; but, unfortunately, not all patients qualify for this invasive surgical approach.
METHODS: Between 1992 and 2000, 64 patients underwent pleurectomy as a palliative treatment for MPM. This retrospective study evaluates the operative outcome and the impact of some prognostic factors on patients' survival. Preoperative evaluation included chest X-ray, CT and/or MRI. Diagnosis was made by pleural biopsy via needle, open, or VATS biopsy. The Kaplan-Meier curve and the Log-Rank test were used to analyze the data.
RESULTS: The median age of the study group was 65 (with a range of 29-84 years). Thirty-six patients had epithelial histology, and 28 patients had sarcomatoid or mixed type (e.g., epithelial+spindle, epithelial+sarcomatoid). The 30-day mortality rate was 3.1%. The overall survival rate was 43%, 28%, and 10% at 1, 2, and 3 years, respectively. The overall median survival was 9.4 months (ranging from 1.15 to 52.7 months). The overall median survival with epithelial histology (n=36, 56%) was 21.7 months (with a range of 1.4-52.7 months) versus 5.8 months (with a range of 1.15-18.3 months) for the sarcomatoid or mixed type (n=28, 44%), p=0.0001. The morbidity included atrial fibrillation (n=5), wound infection (n=2), prolonged intubation (longer than 24h, n=8), reintubation for respiratory failure (n=2), pulmonary emboli (n=1), UTI (n=16), DVT (n=5), MI (n=4), and postoperative bleeding (n=7). Univariant analysis demonstrated that the only prognostic factors influencing survival in our series was the histologic type. Age, gender, and the affected side of the lung did not affect the median survival.
CONCLUSION: Our results show that pleurectomy can be performed as a means of palliation for advanced-stage disease with a low mortality rate and may, in fact, improve survival in patients with epithelial subtype as compared with historical controls in the literature with no surgical intervention.

Entities:  

Mesh:

Year:  2008        PMID: 18585112     DOI: 10.1016/j.ijsu.2008.04.004

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  8 in total

Review 1.  Malignant pleural mesothelioma.

Authors:  Siva Raja; Sudish C Murthy; David P Mason
Journal:  Curr Oncol Rep       Date:  2011-08       Impact factor: 5.075

Review 2.  Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P/D).

Authors:  Hasan Fevzi Batirel
Journal:  Ann Transl Med       Date:  2017-06

3.  Physical function and health-related quality of life in patients undergoing surgical treatment for malignant pleural mesothelioma.

Authors:  Takashi Tanaka; Shinichiro Morishita; Masaki Hashimoto; Yusuke Itani; Satoshi Mabuchi; Norihiko Kodama; Seiki Hasegawa; Kazuhisa Domen
Journal:  Support Care Cancer       Date:  2017-03-14       Impact factor: 3.603

4.  Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.

Authors:  Lucian R Chirieac; Yin P Hung; Wai Chin Foo; Matthias D Hofer; Paul A VanderLaan; William G Richards; David J Sugarbaker; Raphael Bueno
Journal:  Cancer       Date:  2019-08-07       Impact factor: 6.860

Review 5.  Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy.

Authors:  Seiki Hasegawa; Nobuyuki Kondo; Seiji Matsumoto; Teruhisa Takuwa; Masaki Hashimoto; Hayato Orui; Shunichi Fukuda; Kazue Yoneda; Yoshitomo Okumura; Noriaki Tsubota; Kazuya Fukuoka; Ikuko Torii; Tohru Tsujimura; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2012-01-12       Impact factor: 3.402

6.  Physical function and health-related quality of life in the convalescent phase in surgically treated patients with malignant pleural mesothelioma.

Authors:  Takashi Tanaka; Shinichiro Morishita; Masaki Hashimoto; Toru Nakamichi; Yuki Uchiyama; Seiki Hasegawa; Kazuhisa Domen
Journal:  Support Care Cancer       Date:  2019-02-20       Impact factor: 3.603

7.  Multimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients.

Authors:  Arnulf Holzknecht; Oliver Illini; Maximilian J Hochmair; Dagmar Krenbek; Ulrike Setinek; Florian Huemer; Erwin Bitterlich; Christoph Kaindl; Vladyslav Getman; Ahmet Akan; Michael Weber; Gunther Leobacher; Arschang Valipour; Michael R Mueller; Stefan B Watzka
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

8.  Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

Authors:  Susana Cedrés; Santiago Ponce-Aix; Jon Zugazagoitia; Irene Sansano; Ana Enguita; Alejandro Navarro-Mendivil; Alex Martinez-Marti; Pablo Martinez; Enriqueta Felip
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.